Published in PLoS One on October 11, 2013
The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) (2014) 0.97
Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. PLoS One (2014) 0.82
Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer. Int J Cancer (2016) 0.79
Dysregulation of ubiquitin ligases in cancer. Drug Resist Updat (2015) 0.75
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. BMC Cell Biol (2017) 0.75
Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget (2015) 0.75
An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res (1990) 5.70
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
The Rb/E2F pathway and cancer. Hum Mol Genet (2001) 4.98
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell (2005) 4.16
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol (1998) 3.99
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature (1995) 3.32
p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell (1998) 3.27
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
Ribozymes, riboswitches and beyond: regulation of gene expression without proteins. Nat Rev Genet (2007) 2.52
Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell (2008) 2.46
P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol (2008) 2.43
Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev (1997) 2.37
Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem (1995) 2.35
Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ (1996) 2.18
Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst (2006) 1.88
Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell (2002) 1.70
Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol (1998) 1.69
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A (2006) 1.67
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene (2001) 1.66
Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol (2003) 1.51
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem (2005) 1.47
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res (2006) 1.47
Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene (1994) 1.40
The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol (2010) 1.35
Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol (1994) 1.34
An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem (2003) 1.34
Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res (2003) 1.28
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet (2004) 1.26
Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res (2001) 1.25
Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol (2008) 1.25
Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem (2005) 1.22
Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res (2003) 1.17
MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer (1995) 1.16
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res (2011) 1.16
A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry (2006) 1.13
Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res (1998) 1.07
Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol (2000) 1.06
The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol (2010) 1.02
Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res (2006) 1.02
Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int J Cancer (2001) 1.00
MDM2 and MDM4 splicing: an integral part of the cancer spliceome. Front Biosci (Landmark Ed) (2009) 0.99
The p53 mRNA-Mdm2 interaction. Cell Cycle (2009) 0.97
Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res (2001) 0.97
Mdm2 affects genome stability independent of p53. Cancer Res (2009) 0.96
MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol (1998) 0.96
Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res (2006) 0.95
Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene (2006) 0.89
Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis (2008) 0.88
Regulation of the retinoblastoma-dependent Mdm2 and E2F-1 signaling pathways during neuronal apoptosis. Mol Cell Neurosci (2001) 0.88
MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence. Dis Model Mech (2008) 0.86
Splicing up mdm2 for cancer proteome diversity. Genes Cancer (2012) 0.85
MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14. Int J Oncol (2007) 0.85
MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol Cancer Res (2007) 0.83
The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis. Mol Cancer Res (2009) 0.82
Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene (2004) 0.82
Human DNA polymerase epsilon: enzymologic mechanism and gap-filling synthesis. Biochemistry (1996) 0.77
Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. Int J Surg Pathol (2001) 0.76
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One (2010) 1.79
The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy (2013) 1.71
SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood (2008) 1.61
Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine (2010) 1.51
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem (2005) 1.47
Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A (2012) 1.41
Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle (2012) 1.32
Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomedicine (2008) 1.29
Lipid mediators of autophagy in stress-induced premature senescence of endothelial cells. Am J Physiol Heart Circ Physiol (2008) 1.25
Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int J Nanomedicine (2009) 1.17
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res (2011) 1.16
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine (2009) 1.13
Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomedicine (2009) 1.10
The effect of magnetic nanoparticles of Fe(3)O(4) on immune function in normal ICR mice. Int J Nanomedicine (2010) 1.08
Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine (2012) 1.01
Genome sequence of Rhodococcus sp. strain R04, a polychlorinated-biphenyl biodegrader. J Bacteriol (2011) 1.00
Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem (2002) 1.00
Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. ACS Chem Biol (2007) 0.98
Characterization of (68)Zn uptake, translocation, and accumulation into developing grains and young leaves of high Zn-density rice genotype. J Zhejiang Univ Sci B (2011) 0.98
Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol (2004) 0.97
Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine (2009) 0.96
Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res (2006) 0.95
Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int J Nanomedicine (2009) 0.95
[Preparation of Fe3O4-magnetic nanoparticles loaded with adriamycin and its reversal of multidrug resistance in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.93
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine (2010) 0.92
Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells. Int J Nanomedicine (2008) 0.92
Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J Biol Chem (2003) 0.91
Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry. Chem Res Toxicol (2008) 0.90
(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol (2011) 0.89
Inositol trisphosphate 3-kinase B (InsP3KB) as a physiological modulator of myelopoiesis. Proc Natl Acad Sci U S A (2008) 0.89
DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chem Res Toxicol (2010) 0.89
Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis (2008) 0.88
A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. J Clin Invest (2013) 0.87
Effect of magnetic Fe3O4 nanoparticles with 2-methoxyestradiol on the cell-cycle progression and apoptosis of myelodysplastic syndrome cells. Int J Nanomedicine (2011) 0.87
Advancement of the study on iron metabolism and regulation in tumor cells. Chin J Cancer (2010) 0.86
Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in Raji cells. Int J Nanomedicine (2012) 0.85
Splicing up mdm2 for cancer proteome diversity. Genes Cancer (2012) 0.85
Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells. Hematology (2011) 0.84
Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line. Int J Nanomedicine (2012) 0.82
8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Mol Cancer Ther (2012) 0.81
Daunorubicin-loaded magnetic nanoparticles of Fe(3)O(4) greatly enhance the responses of multidrug-resistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2009) 0.81
Effect of hOGG1 over-expression on cisplatin resistance in esophageal squamous carcinoma cells. Cancer Biother Radiopharm (2013) 0.80
New animal models of Alzheimer's disease that display insulin desensitization in the brain. Rev Neurosci (2013) 0.79
Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle (2015) 0.78
Simultaneous determination of atropine, scopolamine, and anisodamine in Flos daturae by capillary electrophoresis using a capillary coated by graphene oxide. J Sep Sci (2013) 0.78
[Research progress on mechanism of MDS transformation into AML]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2011) 0.78
Splice variants of MDM2 in oncogenesis. Subcell Biochem (2014) 0.77
Effects of magnetic nanoparticle of Fe3O4 on apoptosis induced by Gambogic acid in U937 leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.77
[A new method for 5, 10-methylenetetrahydrofolate reductase single nucleotide polymorphisms genotyping used to study susceptibility of hematological malignancy]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.77
[Effect of tetrandrine, toremifene and their combination on the reversion of multidrug resistance of K562/A02 cell line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2008) 0.75
Prevention of acute graft-versus-host disease by magnetic nanoparticles of Fe₃O₄ combined with cyclosporin A in murine models. Int J Nanomedicine (2011) 0.75
[Effects of sensitized donor lymphocyte infusion on the chimerism and graft-versus-host disease after nonmyeloablative allogeneic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Effect of sodium valproate on human myelodysplastic syndrome cell line SKM-1 and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Induction of immune tolerance for allogenic recipient mice by non-myeloablative bone marrow transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2005) 0.75
[Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2009) 0.75
[Selective elimination of alloreactive donor lymphocytes by using TBI and cyclophosphamide]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.75
[Killing activity in DC and CIK co-culture against hepatocarcinoma cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Effects of hypoxia-inducible factor inhibitor on expression of HIF-1alpha and VEGF and induction of apoptosis in leukemic cell lines]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Auto-hematopoietic stem cell transplantation for multiple myeloma accompanied with amyloidosis in four limbs]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2009) 0.75
Detection of complex karyotype in a myelodysplastic syndrome cell line (MUTZ-1) by metaphase fluorescence in situ hybridization. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Effect of gambogic acid on proliferation of SKM-1 cells and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2013) 0.75
[Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Clinical application of BCR/ABL probes in myeloproliferative disorders]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2013) 0.75
[Analysis of hematopoietic chimerism after non-myeloablative allogeneic peripheral blood stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Alterations of telomerase activity and apoptosis induced by 2-methoxyestradiol in human myelodysplastic syndrome cell line MUTZ-1]. Zhonghua Xue Ye Xue Za Zhi (2007) 0.75
[Effect of Autologous or Allogeneic Anti-CD3 Monoclonal Antibody Activated Killer Cells on Normal Hematopoietic Cells] Zhongguo Shi Yan Xue Ye Xue Za Zhi (2001) 0.75
[Effect of hypoxia inducible factor1-α inhibitor on reversal of multidrug resistance of K562/A02 cell line]. Zhonghua Xue Ye Xue Za Zhi (2010) 0.75
[Effects of platelet-derived membrane microparticles on the proliferation and apoptosis of human umbilical vein endothelial cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.75
[Effect of desferrioxamine on K562/A02 cell line and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2011) 0.75
[Deferasirox--a new oral iron chelator--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Regulation of 2-methoxyestradiol-induced cell apoptosis by mcl-1 and bax genes in myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2009) 0.75
[Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
MDR reversal activity of bromotetrandrine in vitro and in vivo. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2009) 0.75
[Effect of cyclosporine A, raloxifene and their combination on the reversion of multidrug resistance of K562/A02 line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Possible mechanism underlying apoptotic induction effect of vitamin K2 on human MDS cell line MUTZ-1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.75
[Cold storage of rabbit platelet suspension by adding uridine diphosphate galactose]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Influence of magnetic Fe3O4 nanoparticle on functions of lymphocytes and macrophages in mice]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Effect of dendritic cells co-cultured with cytokine induced killer cells on cytotoxicity against drug resistant K562 cells]. Zhonghua Xue Ye Xue Za Zhi (2005) 0.75
[Quantitative microarray-based DNA methylation analysis of E-cadherin gene promoter in acute leukemia]. Zhonghua Zhong Liu Za Zhi (2007) 0.75
[Apoptosis of human myelodysplastic syndrome cell Line MUTZ-1 induced by sodium valproate]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.75
[Gene expression in patients with myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Construction and identification of Mdr-1-shRNA eukaryotic expression vector]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Inducing apoptosis and reversal effect of nilotinib in combination with tetrandrine on multidrug resistance of K562/A02 cell line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2011) 0.75
[Test of activated plasma clotting time to assess efficacy of platelet transfusion]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.75
[Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1]. Ai Zheng (2007) 0.75
Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis. Medicine (Baltimore) (2017) 0.75
[Detection of bcr-abl fusion gene mRNA level in K562/A02 cell line by real-time quantitative RT-PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2011) 0.75
[Study on reversal effect of nilotinib in combination with 5-BrTet on multidrug resistance of K562/A02 cell line]. Zhonghua Xue Ye Xue Za Zhi (2010) 0.75
[Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.75
[Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation]. Zhonghua Zhong Liu Za Zhi (2011) 0.75
[Effects of platelet-derived membrane microparticles on angiogenesis in chick chorioallantoic membranes]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2007) 0.75
[Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2009) 0.75
[Platelet-derived microparticles stimulate proliferation of granulocyte-macrophage progenitor cells from umbilical cord blood]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.75
[Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi (2011) 0.75